Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Genomic Vision to Extend its Strategic R&D Alliance with Quest Diagnostics

Published: Friday, June 14, 2013
Last Updated: Friday, June 14, 2013
Bookmark and Share
Quest Diagnostics will invest in the planned development of a lab-developed test.

Genomic Vision has announced an extension of its strategic alliance agreement with U.S.-based Quest Diagnostics, the world's leading provider of diagnostic information services.

Under the agreement, Quest Diagnostics will invest in the planned development of a lab-developed test for a hereditary genetic disease.

The company will also collaborate with Genomic Vision to automate the testing process and improve turnaround times for tests that employ DNA combing, a technique from Genomic Vision. Additional terms were not disclosed.

"This development is based on the complementary nature of our expertise. The new automated process will help leverage the potential of DNA combing for testing of large populations, which in turn may help improve detection of diseases such as certain cancers and neurological disorders ", stated Aaron Bensimon, CEO of Genomic Vision.

"This development program should make an automated platform available to our customers by the end of 2013, increasing the throughput of our current platform by an order of magnitude", explained Dr. Bensimon.

Genomic Vision and Quest Diagnostics announced a strategic alliance agreement in July 2011 giving Quest exclusive rights in the United States and certain other territories to develop and sell diagnostic tests based on Genomic Vision's molecular combing technology.

Quest Diagnostics (7.4 billion dollars in 2012 revenues with 41,000 employees) has also taken an equity stake in the French biotech company.

Since that time, Quest Diagnostics has adapted the molecular combing technique to a commercial laboratory, streamlined and automated processes and successfully validated an improved molecular combing assay for the genetic disorder facio-scapulo-humeral muscular dystrophy (FSHD). Quest Diagnostics expects to launch the FSHD lab-developed test this summer.

Quest Diagnostics is also exploring market opportunities for a lab-developed test for Lynch Syndrome, which genetically predisposes an individual to colorectal cancer, based on DNA combing.

In 2012, Genomic Vision launched its first test in Europe designed to diagnose facio-scapulo-humeral muscular dystrophy (FSHD), the second most prevalent muscular dystrophy disorder affecting 1 in 10,000 to 1 in 20,000 people.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genomic Vision Receives EUR 473,000 Boost to Technology Development Program
The certification of two of its projects enables the Company to broaden oncology applications and complete technology development.
Tuesday, January 30, 2007
Scientific News
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos